RYTM RHYTHM PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1649904 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY61.0%
TTM net income YoY-0.8%
TTM EPS YoY6.1%
Revenue 3-yr CAGR65.5%
Net income 3-yr CAGR—
Margins
Gross margin88.2%
Operating margin-66.7%
Net margin-69.0%
FCF margin—
EBITDA margin—
Returns
ROE-163.7%
ROA-40.8%
ROIC (approx.)-83.0%
Asset turnover0.59x
Leverage & solvency
Liabilities / assets54.5%
Debt / equity1.17x
Current ratio2.78x
Interest coverage-10.27x
Cash quality & payout
Operating cash flow / net income0.42x
Accruals ratio-23.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $189.76M | $130.13M |
| Cost of revenue | $19.49M | $13.37M |
| Gross profit | $170.26M | $116.76M |
| R&D expense | $167.34M | $237.96M |
| SG&A expense | $194.94M | $144.30M |
| Operating income | -$192.02M | -$265.50M |
| Interest expense | $20.58M | $20.60M |
| Pretax income | -$196.04M | -$260.26M |
| Income tax | $497,000 | $346,000 |
| Net income | -$196.54M | -$260.60M |
| EBITDA | -$191.52M | -$264.80M |
| EPS (basic) | -3.11 | -4.34 |
| EPS (diluted) | -3.11 | -4.34 |
| Weighted avg. shares (diluted) | 64.98M | 61.00M |
| Balance sheet | ||
| Cash & equivalents | $54.30M | $89.14M |
| Short-term investments | $334.65M | $231.43M |
| Receivables | $26.08M | $18.51M |
| Inventory | $25.75M | $18.74M |
| Current assets | $466.92M | $374.20M |
| PP&E, net | $1.10M | $632,000 |
| Intangibles | $5.32M | $6.17M |
| Total assets | $480.20M | $392.27M |
| Current liabilities | $105.94M | $115.52M |
| Short-term debt | $7.30M | $1.54M |
| Long-term debt | $100.89M | $108.27M |
| Total debt | $108.18M | $109.81M |
| Total liabilities | $210.17M | $227.72M |
| Shareholders' equity | $139.07M | $21.73M |
| Net debt | $53.88M | $20.67M |
| Shares outstanding | 67.21M | 62.39M |
| Cash flow statement | ||
| Operating cash flow | -$115.67M | -$113.88M |
| Capital expenditure | $953,000 | $0 |
| Free cash flow | -$116.63M | -$113.88M |
| Investing cash flow | -$137.15M | -$48.17M |
| Financing cash flow | $217.96M | $191.24M |
| Depreciation & amortization | $500,000 | $700,000 |
| Stock-based compensation | $66.82M | $39.68M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.